Skip to main content
Erschienen in: Cardiovascular Diabetology 1/2019

Open Access 01.12.2019 | Original investigation

Impact of serum 1,5-anhydro-d-glucitol level on the prediction of severe coronary artery calcification: an intravascular ultrasound study

verfasst von: Hideki Wada, Tomotaka Dohi, Katsumi Miyauchi, Norihito Takahashi, Hirohisa Endo, Yoshiteru Kato, Manabu Ogita, Iwao Okai, Hiroshi Iwata, Shinya Okazaki, Kikuo Isoda, Kazunori Shimada, Satoru Suwa, Hiroyuki Daida

Erschienen in: Cardiovascular Diabetology | Ausgabe 1/2019

Abstract

Background

A low 1,5-anhydro-d-glucitol (AG) blood level is considered a clinical marker of postprandial hyperglycemia. Previous studies reported that 1,5-AG levels were associated with vascular endothelial dysfunction and coronary artery disease (CAD). However, the association between 1,5-AG levels and coronary artery plaque in patients with CAD is unclear.

Methods

This study included 161 patients who underwent percutaneous coronary intervention for CAD. The culprit plaque characteristics and the extent of coronary calcification, which was measured by the angle of its arc, were assessed by preintervention intravascular ultrasound (IVUS). Patients with chronic kidney disease or glycosylated hemoglobin ≥ 7.0 were excluded. Patients were divided into 2 groups according to serum 1,5-AG levels (< 14.0 μg/mL vs. ≥ 14 μg/mL).

Results

The total atheroma volume and the presence of IVUS-attenuated plaque in the culprit lesions were similar between groups. Calcified plaques were frequently observed in the low 1,5-AG group (p = 0.06). Compared with the high 1,5-AG group, the low 1,5-AG group had significantly higher median maximum calcification (144° vs. 107°, p = 0.03) and more frequent calcified plaques with a maximum calcification angle of ≥ 180° (34.0% vs. 13.2%, p = 0.003). Multivariate logistic regression analysis showed that a low 1,5-AG level was a significant predictor of a greater calcification angle (> 180°) (OR 2.64, 95% CI 1.10–6.29, p = 0.03).

Conclusions

Low 1,5-AG level, which indicated postprandial hyperglycemia, was associated with the severity of coronary artery calcification. Further studies are needed to clarify the effects of postprandial hyperglycemia on coronary artery calcification.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ACS
acute coronary syndrome
1,5-AG
1,5-anhydro-d-glucitol
BP
blood pressure
CAD
coronary artery disease
CI
confidence interval
CSA
cross-sectional area
CT
computed tomography
CVD
cardiovascular disease
DM
diabetes mellitus
EEM
external elastic membrane
IQR
interquartile range
HbA1c
glycosylated hemoglobin
IVUS
intravascular ultrasound
MI
myocardial infarction
OR
odds ratio
PCI
percutaneous coronary intervention
SD
standard deviation
TAV
total atheroma volume

Background

Type 2 diabetes mellitus (DM) is a complex disease that is related to atherosclerotic diseases. Patients with type 2 DM have a higher incidence of cardiovascular disease (CVD) compared with the general population [1, 2]. Increased glycosylated hemoglobin (HbA1c), which is a common marker of long-term glycemic control, had been associated with poor prognosis in patients with DM [3]. Moreover, previous studies demonstrated that postprandial hyperglycemia affected mortality and CVD progression [46]. 1,5-anhydro-d-glucitol (1,5-AG) is a naturally occurring 1-deoxy form of glucose and thought to originate in the diet [7]. Serum 1,5-AG levels have been known to rapidly decrease along with the excretion of glucose in the urine and were reported to better reflect short-term glucose control and postprandial hyperglycemia, compared with HbA1c levels [8, 9]. Some studies have shown that 1,5-AG levels were associated with vascular endothelial dysfunction [10] and superior to HbA1c in detecting the presence of CVD [11, 12]. Our colleagues demonstrated that low 1,5-AG levels predicted the long-term clinical outcomes in CVD patients with HbA1c levels < 7.0% [13, 14]. Therefore, 1,5-AG level might be a useful predictive marker in patients with relatively low HbA1c levels. However, the mechanisms of the relationship between CVD and 1,5-AG level are unclear. In this study, we sought to evaluate the association between 1,5-AG level and culprit coronary plaque findings, including quantitative and qualitative analyses by gray-scale intravascular ultrasound (IVUS), in patients with CVD who underwent percutaneous coronary intervention (PCI).

Methods

Study population

In this prospective, single-center, observational study, 324 consecutive coronary artery disease (CAD) patients who were admitted to Juntendo University Hospital were enrolled from August 2014 to August 2016 (Fig. 1). The inclusion criteria were (1) patients who underwent PCI under IVUS guidance to treat a de novo culprit lesion and (2) patients who were evaluated using IVUS. The exclusion criteria were (1) patients who had in-stent restenosis or a lesion with chronic total occlusion; (2) patients who had chronic kidney disease (CKD), which was defined as an estimated glomerular filtration rate of < 60 mL/min/1.73 m2 that was calculated using the Modification of Diet in Renal Disease equation, modified with a Japanese coefficient using baseline serum creatinine [15]; (3) patients who had HbA1c levels ≥ 7.0% and those under treatment with sodium-glucose co-transporter 2 inhibitors; and (4) patients in whom adequate IVUS images or data on 1,5-AG levels were not obtained. Patients were divided into 2 groups (low 1,5-AG group, < 14.0 µg/mL; high 1,5-AG group, ≥ 14.0 µg/mL).
This study was approved by the Juntendo University ethics committee and was performed in accordance with the Declaration of Helsinki. All participants provided written, informed consent.

Data collection and blood sampling

Data on demographics, CAD risk factors, and medication use were collected from our institutional database. Blood samples were collected in the early morning after overnight fasting, and blood pressure (BP) was measured on admission. Patients with BP > 140/90 mmHg or those receiving antihypertensive drugs were regarded as hypertensive. Dyslipidemia was defined as low-density lipoprotein cholesterol ≥ 140 mg/dL, high-density lipoprotein cholesterol ≤ 40 mg/dL, triglycerides ≥ 150 mg/dL, or current treatment with statins and/or lipid-lowering agents [16]. DM was defined as either an HbA1c ≥ 6.5% or use of medications, such as insulin or oral hypoglycemic drugs. A current smoker was defined as a person who was a smoker at the time of PCI or who had quit smoking within 1 year before PCI. Acute coronary syndrome (ACS) was defined as acute myocardial infarction (MI) and unstable angina. Acute MI was characterized by elevated cardiac enzymes. Unstable angina was diagnosed in the presence of ischemic symptoms, without the elevation of the enzymes and biomarkers associated with myocardial necrosis.
To measure 1,5-AG levels, blood samples were obtained immediately prior to coronary angiography and stored at − 80 °C until measurement. Serum 1,5-AG levels were measured with a colorimetric method (Nippon Kayaku, Tokyo, Japan) using a Lana 1,5-AG auto liquid automatic analyzer (JCA-BM 8060, JEOL Ltd., Tokyo, Japan).

IVUS image acquisition and analysis

In all study patients, the culprit plaque lesion was evaluated by preintervention IVUS. By comparing pre- and post-PCI IVUS findings, a culprit lesion segment was defined as the lesion that was stented. In this study, the mechanical rotating 40-MHz transducer that was used were from 1 commercially available IVUS systems and catheters (Atlantis Pro2, Boston Scientific Corporation, Natick, MA, USA; View It, Terumo Corporation, Tokyo, Japan). After intracoronary administration of 0.1–0.2 mg nitroglycerin, IVUS imaging of the culprit lesion segment was performed before balloon dilatation or after small (1.5–2.0 mm) balloon dilatation. All IVUS pullback maneuvers were performed automatically at 0.5 mm/s. All measurements were fulfilled at the end of this study. Quantitative and qualitative IVUS analyses were performed according to the criteria of the American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies [17]. The morphological features were diagnosed by careful review of the IVUS images and upon the agreement of the 2 independent experienced cardiologists (H.W. and T.D.) who were blinded to the clinical data. Offline analyses of all imaged segments were performed using computerized planimetry software (QIVUS; Medis Medical Imaging System, Leiden, the Netherlands).
The quantitative IVUS measurements included the external elastic membrane (EEM), lumen cross-sectional area (CSA), and the plaque plus media CSA (EEM–lumen CSA). The plaque burden was calculated as the plaque plus media CSA divided by the lesion EEM CSA multiplied by 100. Total atheroma volume (TAV) was calculated as the sum of the differences between the EEM and the luminal areas across all segments analyzed. Percent atheroma volume was calculated as the proportion of the entire lesion segment occupied by the atherosclerotic plaque. The qualitative IVUS variables included plaque rupture (presence of a cavity that communicated with the lumen with an overlying residual fibrous cap); thrombus (an intraluminal mass, often with a layered, lobulated, or pedunculated appearance); calcification (brighter plaque than adventitia with acoustic shadowing); and ultrasound attenuation behind the plaque in the absence of calcification. The maximum angle of the ultrasound attenuation and the calcification of the lesion were also measured. The remodeling index was calculated as the EEM CSA at the minimal lumen area site divided by the average of the proximal and distal reference EEM CSA. A representative case is shown in Fig. 2.

Statistical analysis

Quantitative data are presented as mean ± standard deviation (SD) or median [interquartile range (IQR)]. Categorical variables are presented as frequencies. Continuous variables were compared using unpaired t-test or the Mann–Whitney U-test, as appropriate. Categorical variables were compared using the Chi-square test. A logistic regression analysis was used to compare the odds ratios (ORs) of the calcified plaque (maximum calcified angle ≥ 180°) between 2 groups (low 1,5-AG and high 1,5-AG). Differences were considered significant at p < 0.05. Statistical analyses were carried out using JMP version 12.0 software (SAS Institute, Cary, NC, USA).

Results

Baseline patient clinical characteristics

In the 161 patients, the median and mean 1,5-AG were 17.6 (IQR 13.4, 23.3) and 18.6 ± 7.1, respectively; of these, 45 patients (28.0%) were assigned to the low 1,5-AG group. The baseline demographics are summarized in Table 1. The mean age of the patients was 64.9 years, 86.3% were men, and the rate of DM was 19.9%. Compared with the patients in the high 1,5-AG group, those in the low 1,5-AG group were more likely to have DM and have higher fasting blood glucose levels. On the other hand, there was no significant difference in the HbA1c levels between the low 1,5-AG and high 1,5-AG groups.
Table 1
Mean baseline characteristics of the patients
 
Overall
n = 161
Low 1,5-AG group
< 14.0 μg/mL
n = 45
High 1,5-AG group
≥ 14.0 µg/mL
n = 116
p value
1,5-Anhydro-d-glucitol, μg/mLa
17.6 [13.4, 23.3]
11.0 [8.6, 12.5]
20.6 [17.3, 25.5]
< 0.0001
Age, years
64.9 ± 11.2
66.3 ± 10.6
64.4 ± 11.4
0.35
Male (%)
139 (86.3)
38 (84.4)
101 (87.1)
0.66
Body mass index, kg/m2
24.8 ± 3.7
24.8 ± 3.7
24.8 ± 3.8
0.96
Hypertension (%)
111 (68.9)
31 (68.9)
80 (69.0)
0.99
Diabetes (%)
32 (19.9)
16 (35.6)
16 (13.8)
0.002
Dyslipidemia (%)
114 (70.8)
32 (71.1)
82 (70.7)
0.96
Current smoker (%)
41 (25.5)
11 (24.4)
30 (25.9)
0.85
Family history of coronary artery disease (%)
45 (28.1)
14 (31.1)
31 (27.0)
0.60
Acute coronary syndrome presentation
30 (18.6)
9 (20.0)
21 (18.1)
0.78
Oral hypoglycemic drugs
20 (12.4)
11 (24.4)
9 (7.8)
0.006
Metformin (%)
1 (0.6)
1 (2.2)
0 (0.0)
0.11
Sulfonylureas (%)
5 (3.1)
5 (11.1)
0 (0.0)
0.0003
Dipeptidyl peptidase-4 inhibitors (%)
17 (10.6)
11 (24.4)
6 (5.2)
0.0008
Others (%)
5 (3.1)
2 (4.4)
3 (2.6)
0.56
Prior statin use, %
120 (74.5)
30 (66.7)
90 (77.6)
0.15
Low-density lipoprotein cholesterol, mg/dL
89.0 ± 23.9
91.4 ± 23.1
88.0 ± 24.3
0.46
High-density lipoprotein cholesterol, mg/dL
45.3 ± 12.1
44.6 ± 11.8
45.6 ± 12.3
0.64
Triglycerides, mg/dL
126.6 ± 66.8
119.5 ± 67.0
129.4 ± 66.8
0.40
Hemoglobin A1c, %
5.9 ± 0.4
6.0 ± 0.5
5.8 ± 0.4
0.10
Fasting blood glucose, mg/dL
97.3 ± 19.0
106.6 ± 25.8
93.7 ± 14.2
< 0.0001
High-sensitivity C-reactive protein, mg/dLa
0.05 [0.02, 0.13]
0.05 [0.02, 0.12]
0.05 [0.03, 0.15]
0.54
Estimated glomerular filtration rate, mL/min/1.73 m2
83.5 ± 17.9
85.1 ± 19.8
82.9 ± 17.2
0.48
aMedian [interquartile range]

Quantitative and qualitative IVUS findings

A total of 168 culprit lesions were analyzed. The lesion-level findings on coronary angiography and IVUS are shown in Table 2. The overall median minimal lumen area, percentage atheroma volume, and remodeling index were 2.1 mm2, 60.8%, and 1.1, respectively. There were no significant differences in the quantitative parameters, such as plaque burden at the minimal lumen area, percent atheroma volume, total atheroma volume, and remodeling index between the low 1,5-AG and high 1,5-AG groups.
Table 2
Mean coronary angiography and IVUS findings of the lesions
 
Overall
(n = 168)
Low 1,5-AG group
< 14.0 μg/mL
(n = 47)
High 1,5-AG group
≥ 14.0 μg/mL
(n = 121)
p value
Quantitative coronary angiography
 Culprit vessel
   
0.83
  Left anterior descending artery (%)
84 (50.0)
24 (51.1)
60 (49.6)
 
  Right coronary artery (%)
48 (28.6)
15 (31.9)
33 (27.3)
 
  Left circumflex artery (%)
31 (18.5)
7 (14.9)
24 (19.8)
 
  Others
5 (3.0)
1 (2.1)
4 (3.3)
 
 Total length of the lesions, mma
23.9 [16.1, 32.1]
24.1 [15.9, 36.8]
23.6 [17.7, 32.0]
0.90
IVUS findings
 Quantitative parameters
    
  MLA, mm2 a
2.1 [1.8, 2.7]
2.1 [1.8, 2.6]
2.1 [1.7, 2.7]
0.45
  EEM at MLA site, mm2 a
12.3 [9.5, 16.3]
12.0 [8.4, 17.8]
12.4 [9.5, 15.9]
0.88
  Area of stenosis at the MLA, %a
81.8 [75.5, 87.3]
78.6 [74.3, 88.5]
81.9 [76.0, 87.2]
0.41
  Percent atheroma volume, %a
60.8 [53.9, 67.5]
61.9 [54.3, 67.1]
60.1 [53.6, 68.4]
0.81
  Total atheroma volume, mm3 a
194.8 [139.9, 287.0]
206.9 [140.3, 320.9]
188.7 [136.1, 264.1]
0.52
  Total atheroma volumenormalized, mm3 a
205.9 [146.6, 264.2]
216.4 [137.4, 278.3]
205.2 [147.2, 253.9]
0.57
  Remodeling indexa
1.1 [1.0, 1.2]
1.1 [1.0, 1.2]
1.1 [1.0, 1.2]
0.83
 Qualitative assessment and parameters
  Culprit plaque type
   
0.31
   Soft
63 (37.5)
19 (40.4)
44 (36.4)
 
   Fibrous
45 (26.8)
8 (17.0))
37 (30.6)
 
   Calcified
29 (17.3)
10 (21.3)
19 (15.7)
 
   Mixed
31 (18.5)
10 (21.3)
21 (17.4)
 
  Plaque rupture (%)
39 (23.2)
14 (29.8)
25 (20.7)
0.21
  Thrombosis on IVUS (%)
18 (10.7)
6 (12.8)
12 (9.9)
0.60
  Calcified nodule (%)
21 (12.5)
6 (12.8)
15 (12.4)
0.95
  Ultrasound attenuation (%)
103 (61.3)
31 (66.0)
72 (59.5)
0.44
  Maximum attenuation angle, ° a
137 [108, 178]
141 [108, 187]
136 [110, 172]
0.99
  Calcified lesion (%)
103 (61.3)
34 (72.3)
69 (57.0)
0.06
  Maximum calcium angle, ° a
115 [84, 228]
144 [88, 276]
107 [80, 156]
0.03
  Maximum calcium arch ≥ 130° (%)
45 (26.8)
19 (40.4)
26 (21.5)
0.01
  Maximum calcium arch ≥ 180° (%)
32 (19.1)
16 (34.0)
16 (13.2)
0.002
EEM external elastic membrane, IVUS intravascular ultrasound, MLA minimal lumen area
aMedian [interquartile range]
In the overall qualitative analysis, 37.5% and 17.3% of the plaques were described as soft and calcific, respectively. There was no significant difference in the culprit plaque type between the groups. Similarly, the frequency of plaque rupture and calcified nodules did not differ between the groups. The frequency of calcified lesion tended to be higher in the low 1,5-AG group than in the high 1,5-AG group (72.3% vs. 57.0%; p = 0.06); whereas the frequency of ultrasound attenuation was similar between the groups. The median maximum calcification angle was significantly higher in the low 1,5-AG group than in the high 1,5-AG group (144° vs. 107°, p = 0.03). Plaques with a maximum calcification angle of > 180° were more frequently observed in the low 1,5-AG group than in the high 1,5-AG group (34.0% vs. 13.2%; p = 0.01).

Multivariate logistic regression analysis

The univariate logistic regression analysis showed that low 1,5-AG level was significantly associated with a greater calcification angle (> 180°) (OR 3.39, 95% CI 1.52–7.60; p = 0.003). To determine the value of serum 1,5-AG, a multivariate logistic regression analysis was conducted. The variables for which the unadjusted p value was < 0.10 in the univariate analysis were included in the multivariate model for greater calcification angle. In the multivariate model (Table 3), the independent predictors of a greater calcification angle were low 1,5-AG level (adjusted OR 2.64, 95% confidence interval (CI) 1.10–6.29; p = 0.03) and the presence of diabetes (OR 2.99, 95% CI 1.20–7.33; p = 0.02).
Table 3
Multivariate logistic regression analysis for the factors that affect maximum calcification angle ≥ 180°
 
Univariate
Multivariate
Odds ratio
95% CI
p value
Odds ratio
95% CI
p value
1,5-Anhydro-d-glucitol < 14.0 μg/mL
3.39
1.52–7.60
0.003
2.64
1.10–6.29
0.03
Acute coronary syndrome on admission
0.42
0.10–1.29
0.14
   
Age
1.04
1.01–1.08
0.03
1.04
0.996–1.081
0.08
Body mass index
0.97
0.87-1.08
0.59
   
Current smoker
1.00
0.39–2.36
1.00
   
Diabetes
4.03
1.74–9.33
0.001
2.99
1.20–7.33
0.02
Dyslipidemia
1.54
0.64–4.12
0.34
   
Family history
0.90
0.37–2.05
0.80
   
Hypertension
2.76
1.07–8.56
0.03
2.60
0.95–8.45
0.06
Male
0.82
0.30–2.67
0.73
   
Statin use on admission
0.68
0.30–1.63
0.37
   
CI confidence interval

Discussion

In the present study, the association between 1,5-AG level and culprit coronary plaque findings in CVD patients who underwent PCI was examined. The major findings of the present study were (1) compared with patients in the high 1,5-AG group, those in the low 1,5-AG group were more likely to have a higher fasting blood glucose levels despite similar HbA1c levels; (2) plaques with a maximum calcification angle of > 180° were more frequently observed in the low 1,5-AG group than in the high 1,5-AG group; and (3) low 1,5-AG level was an independent predictor of a greater calcification angle. Overall, our results showed that low 1,5-AG was associated with more severe plaque calcification, which is a discriminator of plaque atherosclerosis.
1,5-AG is a monosaccharide that can be primarily obtained from dietary sources. The concentrations of 1,5-AG in blood and tissues are maintained constant, because the amount filtered by the glomeruli is reabsorbed in the renal proximal tubule. Reabsorption is competitively inhibited by glucose. In the setting hyperglycemia, 1,5-AG is excreted in the urine, and its serum level decreases rapidly [7]. Therefore, serum 1,5-AG level is considered a clinical marker of short-term glycemic status. In addition, 1,5-AG had been reported to reflect glycemic excursions, often in the postprandial state, more robustly than HbA1c, in patients with moderately controlled DM [8]. No differences in 1,5-AG levels were found in patients with markedly different estimated glomerular filtration rates [18], and these levels were not influenced by administration of a gliptin compound [19]. Serum 1,5-AG concentration is a marker for hyperglycemia and may be particularly useful as an indicator for short-term glycemic excursions [20] and is significantly higher in DM patients [21]. Finally, 1,5-AG might suppress the blood glucose elevation through inhibition of sucrase and intestinal glucose absorption [22].
HbA1c is a well-known useful maker for the diagnosis of DM and glycemic control. Elevated HbA1c had been associated with increased risk of cardiovascular events [3, 23, 24], and a target of < 7.0% had been established by the American Diabetes Association [25]. However, despite the beneficial effects of lowering HbA1c level to < 7.0% on macrovascular disease, the risks for macrovascular complications remain [26, 27]. Accordingly, comprehensive evaluation, in addition to that of HbA1c, may be necessary for the prevention of macrovascular diseases, especially in patients with relatively low HbA1c levels.
Our colleagues have demonstrated that low 1,5-AG levels predicted the long-term clinical outcomes in both ACS and stable CAD patients with HbA1c levels < 7.0% [13, 14]. They considered that 1,5-AG, which detected postprandial hyperglycemia, may be a useful marker for risk stratification in CAD patients with HbA1c < 7.0%. In the present study, we showed that a lower 1,5-AG was associated with more severe plaque calcification, as detected by IVUS imaging. Interestingly, coronary atheroma volume or plaque burden were not significantly associated with serum 1,5-AG levels. Postprandial hyperglycemia might not affect plaque quantitative parameters among patients with relatively low HbA1c levels and preserved renal function. Coronary calcification had been recognized to be associated with atherosclerosis [28] and is an established predictor of future cardiac events [2931]. Coronary artery calcification is generally related with the extent of CAD. In a histologic study, Sangiorgi et al. reported a significant association between coronary calcification area and plaque volume [32]. In addition, studies on IVUS and computed tomography (CT) showed an association between coronary artery calcification and extent of atherosclerosis plaque [33, 34]. Coronary artery calcification tended to be higher in patients with DM, correlated with total plaque burden, and was an independent risk factor for adverse cardiac events [34, 35]. Medial artery calcification, which is a non-obstructive condition leading to related artery compliance, is known a risk factor of future cardiovascular events among patients with DM [36]. Previous in vivo experiments reported that diabetes promote vascular calcification in part by recruiting adventitial cell with osteogenic potential [37]. So, osteopontin, an osteoblast matrix protein, is thought to play a role in the development of vascular complication among patients with diabetes [38]. Previous studies have shown the association between elevated HbA1c and coronary artery calcification using CT [39, 40]. In a study on 2076 participants without DM, Carson et al. evaluated the predictive value of HbA1c using CT at baseline and after a 5-year follow-up [39]. They showed that higher HbA1c was independently associated with advanced coronary artery calcification and calcification progression. Our study demonstrated that low 1,5-AG level was related with the incidence of severe coronary calcification, independent of the other risk factors. Furthermore, patients with CKD, which had been recognized a strong risk factor for coronary artery calcification, were excluded in the present study. Therefore, among patients with relatively low HbA1c and without CKD, 1,5-AG might be useful marker to predict the incidence of severe coronary artery calcification and future cardiovascular events.
This study had several limitations. First, as a single-center, observational study on a small patient cohort, unknown confounding factors might have affected the outcomes. Studies with large sample size and racial diversity would be more effective in evaluating the value of 1,5-AG levels. Second, we detected lesion calcifications using gray-scale IVUS only. Although the calcium thickness or volume could not be calculated by IVUS, these can be easily used to detect lesion calcification [41, 42]. Finally, we don’t have any vitro experiments that would help support the results of the present study. Previous study demonstrated that advanced glycation end products induce calcification of vascular smooth muscle cells by osteoblast-like differentiation of smooth muscle cells [43]. Further studies to prove the association between low 1,5-AG levels and coronary calcification are needed.

Conclusions

This study found that low 1,5-AG level, which indicated postprandial hyperglycemia, was associated with the severity of coronary artery calcification. Further studies are needed to confirm the independent effects of postprandial hyperglycemia on coronary artery calcification.

Acknowledgements

The authors are grateful to the staff of the Department of Cardiovascular Medicine at Juntendo University and the Department of Cardiovascular Medicine at Juntendo University Shizuoka Hospital. The authors also appreciate the secretarial assistance of Ms. Yumi Nozawa.
This study was approved by the institutional review board at the Juntendo University Hospital. All participants provided written informed consent.
Participants were informed of data sharing with their name and identity hidden per consent.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035–8.CrossRef Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035–8.CrossRef
2.
Zurück zum Zitat Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–18.CrossRef Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–18.CrossRef
3.
Zurück zum Zitat Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.CrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.CrossRef
4.
Zurück zum Zitat Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44(12):2107–14.CrossRef Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44(12):2107–14.CrossRef
5.
Zurück zum Zitat Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J. Postprandial glucose regulation and diabetic complications. Arch Intern Med. 2004;164(19):2090–5.CrossRef Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J. Postprandial glucose regulation and diabetic complications. Arch Intern Med. 2004;164(19):2090–5.CrossRef
6.
Zurück zum Zitat Gohbara M, Hibi K, Mitsuhashi T, Maejima N, Iwahashi N, Kataoka S, Akiyama E, Tsukahara K, Kosuge M, Ebina T, et al. Glycemic variability on continuous glucose monitoring system correlates with non-culprit vessel coronary plaque vulnerability in patients with first-episode acute coronary syndrome—optical coherence tomography study. Circ J. 2016;80(1):202–10.CrossRef Gohbara M, Hibi K, Mitsuhashi T, Maejima N, Iwahashi N, Kataoka S, Akiyama E, Tsukahara K, Kosuge M, Ebina T, et al. Glycemic variability on continuous glucose monitoring system correlates with non-culprit vessel coronary plaque vulnerability in patients with first-episode acute coronary syndrome—optical coherence tomography study. Circ J. 2016;80(1):202–10.CrossRef
7.
Zurück zum Zitat Dungan KM. 1,5-Anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008;8(1):9–19.CrossRef Dungan KM. 1,5-Anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008;8(1):9–19.CrossRef
8.
Zurück zum Zitat Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29(6):1214–9.CrossRef Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29(6):1214–9.CrossRef
9.
Zurück zum Zitat Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996;347(9014):1514–8.CrossRef Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996;347(9014):1514–8.CrossRef
10.
Zurück zum Zitat Torimoto K, Okada Y, Mori H, Tanaka Y. Low levels of 1,5-anhydro-d-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. Cardiovasc Diabetol. 2014;13:99.CrossRef Torimoto K, Okada Y, Mori H, Tanaka Y. Low levels of 1,5-anhydro-d-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. Cardiovasc Diabetol. 2014;13:99.CrossRef
11.
Zurück zum Zitat Ikeda N, Hara H, Hiroi Y. 1,5-Anhydro-d-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol. 2014;64(4):297–301.CrossRef Ikeda N, Hara H, Hiroi Y. 1,5-Anhydro-d-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol. 2014;64(4):297–301.CrossRef
12.
Zurück zum Zitat Ikeda N, Hara H, Hiroi Y, Nakamura M. Impact of serum 1,5-anhydro-d-glucitol level on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease. Atherosclerosis. 2016;253:1–6.CrossRef Ikeda N, Hara H, Hiroi Y, Nakamura M. Impact of serum 1,5-anhydro-d-glucitol level on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease. Atherosclerosis. 2016;253:1–6.CrossRef
13.
Zurück zum Zitat Ouchi S, Shimada K, Miyazaki T, Takahashi S, Sugita Y, Shimizu M, Murata A, Kadoguchi T, Kato T, Aikawa T, et al. Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0. Cardiovasc Diabetol. 2017;16(1):151.CrossRef Ouchi S, Shimada K, Miyazaki T, Takahashi S, Sugita Y, Shimizu M, Murata A, Kadoguchi T, Kato T, Aikawa T, et al. Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0. Cardiovasc Diabetol. 2017;16(1):151.CrossRef
14.
Zurück zum Zitat Takahashi S, Shimada K, Miyauchi K, Miyazaki T, Sai E, Ogita M, Tsuboi S, Tamura H, Okazaki S, Shiozawa T, et al. Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. Cardiovasc Diabetol. 2016;15(1):145.CrossRef Takahashi S, Shimada K, Miyauchi K, Miyazaki T, Sai E, Ogita M, Tsuboi S, Tamura H, Okazaki S, Shiozawa T, et al. Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. Cardiovasc Diabetol. 2016;15(1):145.CrossRef
15.
Zurück zum Zitat Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRef
16.
Zurück zum Zitat Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, et al. Diagnostic criteria for dyslipidemia. J Atheroscler Thromb. 2013;20(8):655–60.CrossRef Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, et al. Diagnostic criteria for dyslipidemia. J Atheroscler Thromb. 2013;20(8):655–60.CrossRef
17.
Zurück zum Zitat Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37(5):1478–92.CrossRef Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37(5):1478–92.CrossRef
18.
Zurück zum Zitat Kakuta K, Dohi K, Miyoshi M, Yamanaka T, Kawamura M, Masuda J, Kurita T, Ogura T, Yamada N, Sumida Y, et al. Impact of renal function on the underlying pathophysiology of coronary plaque composition in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):131.CrossRef Kakuta K, Dohi K, Miyoshi M, Yamanaka T, Kawamura M, Masuda J, Kurita T, Ogura T, Yamada N, Sumida Y, et al. Impact of renal function on the underlying pathophysiology of coronary plaque composition in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):131.CrossRef
19.
Zurück zum Zitat Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16(1):63.CrossRef Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16(1):63.CrossRef
20.
Zurück zum Zitat Ma C, Sheng J, Liu Z, Guo M. Excretion rates of 1,5-anhydro-d-glucitol, uric acid and microalbuminuria as glycemic control indexes in patients with type 2 diabetes. Sci Rep. 2017;7:44291.CrossRef Ma C, Sheng J, Liu Z, Guo M. Excretion rates of 1,5-anhydro-d-glucitol, uric acid and microalbuminuria as glycemic control indexes in patients with type 2 diabetes. Sci Rep. 2017;7:44291.CrossRef
21.
Zurück zum Zitat Yoshida N, Yamamoto H, Shinke T, Otake H, Kuroda M, Terashita D, Takahashi H, Sakaguchi K, Hirota Y, Emoto T, et al. Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study. Cardiovasc Diabetol. 2017;16(1):96.CrossRef Yoshida N, Yamamoto H, Shinke T, Otake H, Kuroda M, Terashita D, Takahashi H, Sakaguchi K, Hirota Y, Emoto T, et al. Impact of CD14(++)CD16(+) monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study. Cardiovasc Diabetol. 2017;16(1):96.CrossRef
22.
Zurück zum Zitat Nakamura S, Tanabe K, Yoshinaga K, Shimura F, Oku T. Effects of 1,5-anhydroglucitol on postprandial blood glucose and insulin levels and hydrogen excretion in rats and healthy humans. Br J Nutr. 2017;118(2):81–91.CrossRef Nakamura S, Tanabe K, Yoshinaga K, Shimura F, Oku T. Effects of 1,5-anhydroglucitol on postprandial blood glucose and insulin levels and hydrogen excretion in rats and healthy humans. Br J Nutr. 2017;118(2):81–91.CrossRef
23.
Zurück zum Zitat Palta P, Huang ES, Kalyani RR, Golden SH, Yeh HC. Hemoglobin A1c and mortality in older adults with and without diabetes: results from the national health and nutrition examination surveys (1988–2011). Diabetes Care. 2017;40(4):453–60.CrossRef Palta P, Huang ES, Kalyani RR, Golden SH, Yeh HC. Hemoglobin A1c and mortality in older adults with and without diabetes: results from the national health and nutrition examination surveys (1988–2011). Diabetes Care. 2017;40(4):453–60.CrossRef
24.
Zurück zum Zitat Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, Wilson PWF, Phillips LS. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8(4):e011295.CrossRef Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, Wilson PWF, Phillips LS. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8(4):e011295.CrossRef
25.
Zurück zum Zitat American Diabetes Association. Glycemic targets. Diabetes Care. 2016;39(Suppl 1):S39–46. American Diabetes Association. Glycemic targets. Diabetes Care. 2016;39(Suppl 1):S39–46.
26.
Zurück zum Zitat Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.
27.
Zurück zum Zitat Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRef Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRef
28.
Zurück zum Zitat Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol. 2014;34(4):724–36.CrossRef Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol. 2014;34(4):724–36.CrossRef
29.
Zurück zum Zitat Williams MC, Moss AJ, Dweck M, Adamson PD, Alam S, Hunter A, Shah ASV, Pawade T, Weir-McCall JR, Roditi G, et al. Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-HEART study. J Am Coll Cardiol. 2019;73(3):291–301.CrossRef Williams MC, Moss AJ, Dweck M, Adamson PD, Alam S, Hunter A, Shah ASV, Pawade T, Weir-McCall JR, Roditi G, et al. Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-HEART study. J Am Coll Cardiol. 2019;73(3):291–301.CrossRef
30.
Zurück zum Zitat Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, Carr JJ, Budoff MJ, Allison MA. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014;311(3):271–8.CrossRef Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, Carr JJ, Budoff MJ, Allison MA. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014;311(3):271–8.CrossRef
31.
Zurück zum Zitat Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210–5.CrossRef Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210–5.CrossRef
32.
Zurück zum Zitat Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, Schwartz RS. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol. 1998;31(1):126–33.CrossRef Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, Schwartz RS. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol. 1998;31(1):126–33.CrossRef
33.
Zurück zum Zitat Baumgart D, Schmermund A, Goerge G, Haude M, Ge J, Adamzik M, Sehnert C, Altmaier K, Groenemeyer D, Seibel R, et al. Comparison of electron beam computed tomography with intracoronary ultrasound and coronary angiography for detection of coronary atherosclerosis. J Am Coll Cardiol. 1997;30(1):57–64.CrossRef Baumgart D, Schmermund A, Goerge G, Haude M, Ge J, Adamzik M, Sehnert C, Altmaier K, Groenemeyer D, Seibel R, et al. Comparison of electron beam computed tomography with intracoronary ultrasound and coronary angiography for detection of coronary atherosclerosis. J Am Coll Cardiol. 1997;30(1):57–64.CrossRef
34.
Zurück zum Zitat Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation. 1995;92(8):2157–62.CrossRef Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation. 1995;92(8):2157–62.CrossRef
35.
Zurück zum Zitat Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43(9):1663–9.CrossRef Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43(9):1663–9.CrossRef
36.
Zurück zum Zitat Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16(8):978–83.CrossRef Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16(8):978–83.CrossRef
37.
Zurück zum Zitat Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem. 1998;273(46):30427–34.CrossRef Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem. 1998;273(46):30427–34.CrossRef
38.
Zurück zum Zitat Mori S, Takemoto M, Yokote K, Asaumi S, Saito Y. Hyperglycemia-induced alteration of vascular smooth muscle phenotype. J Diabetes Complicat. 2002;16(1):65–8.CrossRef Mori S, Takemoto M, Yokote K, Asaumi S, Saito Y. Hyperglycemia-induced alteration of vascular smooth muscle phenotype. J Diabetes Complicat. 2002;16(1):65–8.CrossRef
39.
Zurück zum Zitat Carson AP, Steffes MW, Carr JJ, Kim Y, Gross MD, Carnethon MR, Reis JP, Loria CM, Jacobs DR Jr, Lewis CE. Hemoglobin a1c and the progression of coronary artery calcification among adults without diabetes. Diabetes Care. 2015;38(1):66–71.CrossRef Carson AP, Steffes MW, Carr JJ, Kim Y, Gross MD, Carnethon MR, Reis JP, Loria CM, Jacobs DR Jr, Lewis CE. Hemoglobin a1c and the progression of coronary artery calcification among adults without diabetes. Diabetes Care. 2015;38(1):66–71.CrossRef
40.
Zurück zum Zitat Chang Y, Yun KE, Jung HS, Kim CW, Kwon MJ, Sung E, Ryu S. A1C and coronary artery calcification in nondiabetic men and women. Arterioscler Thromb Vasc Biol. 2013;33(8):2026–31.CrossRef Chang Y, Yun KE, Jung HS, Kim CW, Kwon MJ, Sung E, Ryu S. A1C and coronary artery calcification in nondiabetic men and women. Arterioscler Thromb Vasc Biol. 2013;33(8):2026–31.CrossRef
41.
Zurück zum Zitat Friedrich GJ, Moes NY, Muhlberger VA, Gabl C, Mikuz G, Hausmann D, Fitzgerald PJ, Yock PG. Detection of intralesional calcium by intracoronary ultrasound depends on the histologic pattern. Am Heart J. 1994;128(3):435–41.CrossRef Friedrich GJ, Moes NY, Muhlberger VA, Gabl C, Mikuz G, Hausmann D, Fitzgerald PJ, Yock PG. Detection of intralesional calcium by intracoronary ultrasound depends on the histologic pattern. Am Heart J. 1994;128(3):435–41.CrossRef
42.
Zurück zum Zitat Kawasaki M, Bouma BE, Bressner J, Houser SL, Nadkarni SK, MacNeill BD, Jang IK, Fujiwara H, Tearney GJ. Diagnostic accuracy of optical coherence tomography and integrated backscatter intravascular ultrasound images for tissue characterization of human coronary plaques. J Am Coll Cardiol. 2006;48(1):81–8.CrossRef Kawasaki M, Bouma BE, Bressner J, Houser SL, Nadkarni SK, MacNeill BD, Jang IK, Fujiwara H, Tearney GJ. Diagnostic accuracy of optical coherence tomography and integrated backscatter intravascular ultrasound images for tissue characterization of human coronary plaques. J Am Coll Cardiol. 2006;48(1):81–8.CrossRef
43.
Zurück zum Zitat Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res. 2009;46(6):572–80.CrossRef Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res. 2009;46(6):572–80.CrossRef
Metadaten
Titel
Impact of serum 1,5-anhydro-d-glucitol level on the prediction of severe coronary artery calcification: an intravascular ultrasound study
verfasst von
Hideki Wada
Tomotaka Dohi
Katsumi Miyauchi
Norihito Takahashi
Hirohisa Endo
Yoshiteru Kato
Manabu Ogita
Iwao Okai
Hiroshi Iwata
Shinya Okazaki
Kikuo Isoda
Kazunori Shimada
Satoru Suwa
Hiroyuki Daida
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
Cardiovascular Diabetology / Ausgabe 1/2019
Elektronische ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0878-1

Weitere Artikel der Ausgabe 1/2019

Cardiovascular Diabetology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.